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In-Depth Review

Iron Therapy Challenges for the Treatment of
Nondialysis CKD Patients
Francesco Locatelli,* Sandro Mazzaferro,† and Jerry Yee‡

Abstract
The clinical consequences of untreated, severe anemia in patients with nondialysis CKD can be significant, but
disparities exist in the anemia treatment guidelines and position papers issued from working groups and associations across the world. These differ in hemoglobin target and iron levels and their emphasis on various iron
markers and other clinical outcomes. Not surprisingly, disparities are observed in anemia treatment strategies
among patients with nondialysis CKD across different areas of the world. Over the past decade, the prescription
and dosage of both iron therapies and erythropoiesis-stimulating agents have shifted, with notable regional differences observed. Moreover, there is ongoing debate regarding oral versus intravenous administration of iron.
Compared with oral iron therapy, which often leads to gastrointestinal adverse events, low patient adherence, and
low efficacy, intravenous iron administration has been associated with potential serious adverse events, such as
anaphylaxis. New iron–based compounds and drugs currently under development are reviewed to describe their
potential benefits in the treatment of anemia in patients with CKD. New oral compounds, including iron–based
phosphate binders, heme iron polypeptide, and liposomal iron, show different rates of absorption with possibly
different efficacy and improved tolerability. These new potential therapies offer health care providers additional
anemia treatment options for their patients with CKD; however, the management of anemia in the CKD population
continues to present challenges that require prospective studies to identify the optimal iron therapy for patients.
Clin J Am Soc Nephrol 11: 1269–1280, 2016. doi: 10.2215/CJN.00080116

Introduction
Guidelines for treating anemia in patients with CKD,
particularly patients with nondialysis (ND) -CKD,
vary, especially across different areas of the world
(1–8). In addition, the growing number of patients
with CKD and anemia and the increasingly insufﬁcient number of nephrologists have led primary care
physicians, particularly those in the United States, to
take on the burden of care for many of these patients
(9). There are clinical and logistical concerns in treating to correct anemia in this patient population because of the scarcity of evidence regarding treatment
of patients with ND-CKD compared with the dialysis
CKD population. There are several causes, including
the lack of access to facilities for intravenous (iv) administration, conﬂicting reports regarding safety of
treatments, and poor tolerability and efﬁcacy of oral
preparations, particularly in patients with CKD stage
5. These concerns have caused confusion as to how to
optimize anemia therapy for patients with ND-CKD
and led some health care providers to choose not to
treat anemia in these patients at all. However, untreated moderate to severe anemia in patients with
CKD has been associated with left ventricular hypertrophy, congestive heart failure, and coronary heart
disease (9). Additionally, untreated anemia can have
consequences regarding the patient’s overall
health–related quality of life (HRQoL). Moreover,
recent experimental (10) and clinical (11) evidence
points to iron status as a modulator of ﬁbroblast
www.cjasn.org Vol 11 July, 2016

growth factor 23 (FGF23) and phosphate metabolism,
thus broadening iron’s potential clinical implications.
Conversely, the consequence of excess iron can promote oxidative stress, leading to protein oxidation and
lipid peroxidation. These processes may accelerate cellular apoptosis as shown in nonclinical studies; however, the association with advancing cardiovascular
disease is proposed but not yet conﬁrmed (12). A consensus is required to aid health care providers in
choosing the best therapeutic plan to treat iron deﬁciency anemia in patients with ND-CKD. An overview of the current understanding of anemia in
CKD, underlying mechanisms of erythropoiesis, and
iron absorption is provided in Figure 1.
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Current Treatment Guidelines
Taking into account these various anemia therapy
approaches, treatment guidelines and position papers
by a number of societies and working groups across
the world have been developed. Guidance regarding
patients with ND-CKD include the Kidney Disease
Improving Global Outcomes (KDIGO) (1) and the
Kidney Disease Outcomes Quality Initiative (2)
guidelines and position papers from the Canadian
Society of Nephrology (3–6), the National Institute
for Health and Care Excellence (NICE) (7), and European Renal Best Practice (8) (Table 1). Although there
are some exceptions, these guidelines and position
papers are generally consistent regarding the
Copyright © 2016 by the American Society of Nephrology
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Figure 1. | Anemia, erythropoiesis, and iron absorption in normal subjects and patients with CKD. (A) In normal subjects, by inhibiting
hypoxia–inducible factor–prolyl–hydroxylases (HIF-Pro-ase), hypoxia stabilizes hypoxia-inducible factor (HIF), thus increasing its activity. In
time, the HIF signaling cascade increases renal synthesis of erythropoietin (EPO), liver synthesis of ferroportin (FPN), and duodenal synthesis of
divalent metal transporter 1 (DMT1). By targeting duodenal cells, FPN favors iron transfer into blood. In blood, iron is bound to transferrin (Tf)
and transported to transferrin receptor (TfR) –expressing cells. Bone marrow cells supplied with iron and stimulated by EPO can efficiently
increase red blood cell production. (B) In chronic inflammatory states, like chronic renal failure , increments in HIF do not efficiently increase
renal synthesis of EPO or liver synthesis of FPN. This last effect also results from increased liver synthesis of epcidin, an inflammatory cytokine
capable of inhibiting both FPN liver synthesis and its binding to duodenal cells. Intestinal absorption of iron is blunted with possibly increased
intracellular iron concentrations. With lower iron availability and inadequate EPO stimulation, bone marrow cannot efficiently increase red
blood cell production. (C) Iron supply in chronic renal failure can be obtained by either oral or intravenous administration. The oral route can be
regarded as physiologic but is hampered by reduced efficiency of intestinal absorption and gastrointestinal side effects; the unphysiologic
intravenous administration is hindered by possible toxic effects through production of labile plasma iron (LPI). Lines indicate activation, and
dashed lines indicate inhibition. Fe, iron; I.V., intravenous; pO2, partial pressure of oxygen.

deﬁnition of hemoglobin (Hb) thresholds of anemia. However, they are less consistent in recommendations regarding iron supplementation and erythropoiesis–stimulating
agent (ESA) use and deﬁning target Hb ranges and maximum ferritin levels. Regional differences in treatment preferences are also evident, because the position papers from
outside of the United States, including those from the NICE
and the Canadian Society of Nephrology, generally consider HRQoL effects, whereas the United States–based
guidance does not emphasize HRQoL parameters. However, all of the guidelines and position papers agree that

any iron deﬁciency should be addressed before initiating
ESA therapy and suggest that the decision to prescribe
ESAs should be on the basis of Hb levels and clinical factors.
These guidelines and position papers are updated periodically
to reﬂect new research results; however, because of differences in how clinical trial results are evaluated and the lack
of strong evidence supporting particular approaches, the interpretation of these results can be conﬂicting and lead to
widely different treatment recommendations. In particular,
studies of iron therapy have not provided clear results as
opposed to the evidence supporting ESA use.
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Figure 1. | Continued.

As reﬂected in the various criteria used in the guidelines
and position papers described above, the evaluation of
therapies for anemia presents a challenge to health care
providers, because so many measures of effectiveness need
to be considered, including efﬁcacy targets, safety evaluations, and HRQoL. The most frequently used efﬁcacy
measurements to assess anemia therapies are Hb, ferritin
(as a marker of iron stores), and transferrin saturation
(TSAT; as a marker of available iron). Apoferritin is a
hollow protein sphere that surrounds a core of hydrous
ferric oxide, in which up to 4500 iron atoms can be stored
bound to oxygen in the ferric state (13). Although all
ferritins contain the same core structure, there are variations in the ferritin molecule depending on cell type and
function (13,14). Interestingly, serum ferritin is derived
from the same gene sequence as intracellular ferritin;
however, serum ferritin is iron poor, because it consists
predominantly of L-chain subunits, and there may be a
combination of ferritin and apoferritin (not combined
with iron) (15). In addition, there is current controversy
regarding whether serum ferritin contains iron. Ferritin
serves to sequester iron for storage; thus, when intracellular
iron increases, ferritin synthesis increases, and expression
of cell surface transferrin receptors decreases (16). The iron
storage disorder called hereditary hemochromatosis, an autosomal recessive genetic disorder that usually results from
defects in the HFE gene, although rare, should also be
taken into consideration when evaluating patients
with CKD for anemia (17). However, the speciﬁcity and
sensitivity of ferritin and TSAT for the evaluation of iron
status are not ideal, especially when evaluating iron repletion and excess iron, because they can be affected by other
causes, such as inﬂammation (ferritin) and malnutrition
(TSAT), providing misleading results (18).
Consequently, investigation into other biomarkers of
iron deﬁciency has begun. Reticulocyte Hb content has
been shown to be a more stable and sensitive marker of
iron deﬁciency than ferritin or TSAT in a clinical trial of
erythropoietin (EPO) -treated patients on dialysis but is not
routinely tested in patients with ND-CKD (19). Other measures include the percentage of labile plasma iron (20),

soluble transferrin receptor 1 (21), and hepcidin levels
(22,23), but these assays must be further reﬁned before
general use (24,25).
In addition to efﬁcacy measurements, the safety of
treatments to correct iron deﬁciency anemia has become a growing concern, because severity of associated
adverse events (AEs) needs to be carefully monitored. Also,
although often neglected (26), the patient’s overall HRQoL,
including physical functioning, pain, general health and
vitality, social functioning, and mental and emotional
health (27), is another outcome to consider when
choosing a treatment plan and biomarker targets. For example, HRQoL should be considered when choosing an
upper Hb target, particularly in younger patients without
comorbidities, because physical activity would be important to most of these patients.

ESA Therapy
Since the approval of recombinant human EPO by the
Food and Drug Administration (FDA) in 1989, ESAs have
become a key component of anemia treatment plans for
patients with CKD. Therapy with ESAs is intended to
stimulate erythropoiesis and consequently, increase Hb
levels; however, as described above, target Hb levels are
debated as well as the correlation between high Hb levels
and HRQoL. Some studies have shown that higher Hb
levels have a signiﬁcant association with improved HRQoL
scores, including both physical and mental summary scores
and general health scores (28,29). In the Cardiovascular
Risk Reduction by Early Anemia Treatment with Epoetin
Beta Trial, signiﬁcantly better HRQoL measures were observed in the group treated with epoetin to maintain high
Hb levels (130–150 g/L) over the group with a lower Hb
target (105–115 g/L) (30). In the Correction of Hemoglobin
and Outcomes in Renal insufﬁciency (CHOIR) Study, primary analysis of the composite events of death, myocardial
infarction, hospitalization caused by congestive heart failure, and stroke showed a higher rate in patients with NDCKD treated with weekly epoetin targeting a higher Hb
level compared with those targeting a lower Hb level
(135 versus 113 g/L; 17% versus 13.5%; P50.03) (31).

Hb,130 g/L in
men .15 yr;
Hb,120 g/L
in women
.15 yr

Hb,135 g/L in
adult men;
Hb,120 g/L
in adult
women

Hb,135 g/L in
men $18 yr;
Hb,120 g/L
in women
$18 yr

Hb,110 g/L or
development
of symptoms
attributable
to anemia
(tiredness,
shortness
of breath,
lethargy, and
palpitations)

KDOQI (2,84)

Canadian
Society of
Nephrology
(3–6,85)

NICE (7)

Diagnosis of
Anemia

KDIGO (1,83)

Guideline
1- to 3-mo trial of oral iron or
iv ironb if TSAT is ,30%
and ferritin is ,500 mg/L
or ESA therapy is to be
avoided or decreased (if
already on ESA therapy)

Initiate ESA therapy in those
with Hb,100 g/L after
all other correctable
causes of anemia have
been addressed and
symptoms of anemia
are present and for
avoiding transfusions;
therapy should be
individualized for
each patienta
Initial ESA dose and ESA
dose adjustments
determined by the
patient’s Hb level, target
Hb level, rate of increase
in Hb level, and clinical
circumstancesc
Initiate ESA therapy when
iron stores have been
corrected, other
reversible causes of
anemia have been
treated, and Hb level is
sustained at ,100 g/L in
patients not receiving
ESA therapye; for
patients receiving ESA
therapy, target Hb is
110 g/L
ESA therapy should not be
initiated in the presence
of absolute iron
deﬁciency without also
managing the iron
deﬁciency; ESAs not
recommended in
the presence of
comorbidities or a
prognosis that is likely to
negate the beneﬁts of
correcting the anemiag
Oral or iv iron to maintain
hypochromic RBC,
reticulocyte, or TSAT and
ferritin targets

Oral or iv iron to maintain
target concentrations of
TSAT and ferritinf; iron is
not recommended
for patients without
evidence of classic iron
deﬁciency whose Hb is
.110 g/L

Oral or iv iron administered
to maintain ferritin
.100 mg/L and
TSAT.20% during ESA
treatmentd

Iron Use

ESA Use

100–120 g/L; rate
of Hb increase
should be
between 10
and 20 g/L per
mo in patients
on ESA
therapyh

Hb.110 g/L;
ESA-treated
patients
should not be
routinely
maintained at
Hb$130 g/L
Hb,110 g/L
(acceptable Hb
range 5100–
120 g/L)

Hb#115 g/L in
adults on ESA
therapy but
should be on
the basis of
individual
patients

Hb Target

Table 1. Summary of current clinical guidelines to treat anemia in adult patients with nondialysis-dependent CKD

Not recommended:
androgens;
insufﬁcient evidence
to recommend:
L-carnitine, vitamin
C, ultrapure
dialysis,
pentoxifylline,
statins, vitamin B6,
and quotidian
dialysis
Not recommended:
androgens, vitamin
C, folic acid, and
carnitine

Does not
recommend
monitoring
phosphorus for
stage 3 CKD;
stages 4 and 5
CKD: Maintain
within normal
range

Recommend
following
British,
American, and
European
treatment
guidelines
Recommend using
hypochromic RBC
.6% (unless ferritin is
.800 mg/L) or
reticulocyte count
.29 pg (unless ferritin is
.800 mg/L); if tests
are not available,
TSAT.20%/ferritin
.100 mg/L; maintain
ferritin ,800 mg/L in
patients on iron therapy

TSAT.20%/ferritin
.100 mg/L; iron
should be considered
if patient is below
target Hb or requires
high ESA doses and
has ferritin .800 mg/L
and TSAT,25%

Not routinely
recommended:
L-carnitine and
ascorbate; not
recommended:
androgens
Stages 3 and 4 CKD:
$2.76 and ,4.61
mg/dl; stage 5
CKD: .3.50 and
,5.51 mg/dl

TSAT$20%/ferritin
.100 and ,500 mg/L

Not recommended:
androgens, vitamin
C, vitamin D,
vitamin E, folic acid,
L-carnitine, and
pentoxifylline

Adjuvants

CKD stages 3–5:
Maintain serum
phosphorus
within the
normal range

Phosphorus
Target

TSAT.30%/ferritin
.500 mg/L

TSAT/Ferritin
Target
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Hb,135 g/L in
adult men
#70 yr;
Hb,132 g/L
in adult men
.70 yr;
Hb,120 g/L
in adult
women

Diagnosis of
Anemia
Iron Use
Oral or iv iron if TSAT is
,20% and ferritin is
,100 mg/L or if Hb
increases without ESA
therapy, TSAT is ,25%,
and ferritin is ,200 mg/L;
in patients on ESA
therapy in whom increase
in Hb or decrease in ESA
dose is desired, oral or iv
iron may be given when
TSAT is ,30% and ferritin
is ,300 mg/L

ESA Use

In low-risk patients or those
in whom a clear beneﬁt in
quality of life can be
foreseen, ESA therapy
can be considered at
Hb,120 g/L; in highrisk patients, ESA
therapy should be
initiated at Hb values
between 90 and 100 g/Li

100–120 g/L; not
.130 g/L for
patients
receiving ESA
therapy;
approximately
100 g/L in
high-risk
patients

Hb Target
TSAT$20%/ferritin 5
100 mg/L; should
not exceed
TSAT.30%/ferritin
.500 mg/L

TSAT/Ferritin
Target
For CKD stages
3–5, maintain
within normal
range

Phosphorus
Target
Not recommended

Adjuvants

ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; TSAT, saturated transferrin; KDIGO, Kidney Disease Improving Global Outcomes; iv, intravenous; KDOQI, Kidney Disease Outcomes
Quality Initiative; NICE, National Institute for Health and Care Excellence; RBC, red blood cell; ERBP, European Renal Best Practice.
a
ESA dosing should be on the basis of the individual patient Hb, body weight, and clinical circumstances and should be adjusted on the basis of Hb, rate of change in Hb, current ESA dose, and
clinical circumstances. The choice of ESA should be on the basis of the balance of pharmacodynamics, safety information, clinical outcome data, cost, and availability. Subcutaneous dosing is
recommended for administration of ESA therapy to patients with nondialysis CKD. Initiation of ESA therapy should be with great caution, if at all, in patients with active malignancy or a history
of stroke.
b
The route of iron administration should be on the basis of the severity of iron deﬁciency, the availability of venous access, response to prior oral iron therapy, side effects with prior iron therapy,
patient compliance, and cost.
c
The route of ESA administration should be determined by the CKD stage, treatment setting, efﬁcacy, safety, and class of ESA used in adults. The anticipated frequency and pain of administration and the potential effects on the child and family should also be considered in pediatric patients. Convenience favors subcutaneous administration and less frequent ESA administration
in adult patients with nondialysis CKD.
d
Clinicians should judge the individual patient’s clinical status and ESA responsiveness and base iron treatment decisions on this assessment.
e
ESAs should be administered subcutaneously on the basis of improved efﬁcacy and convenience.
f
Oral iron is the preferred ﬁrst–line therapy in patients with nondialysis CKD. In patients who do not meet serum ferritin or TSAT targets on oral iron or in whom oral iron is not tolerated, iv iron
may be used. The medical decision regarding the use of iron therapy should be guided by results of iron status tests together with Hb levels, ESA dose, and patient status.
g
When ESA has been initiated, the effectiveness of the ESA should be assessed after an agreed on interval. Where appropriate, a mutual decision between the clinician, the patient with anemia
and CKD, and the family/caregivers should be made on whether to continue ESA therapy. The patient and clinician should agree to the route of ESA administration taking into account the
individual patient’s clinical course, pain of injection, frequency of administration, lifestyle and preferences, efﬁcacy, and cost.
h
When determining individual Hb targets for patients with anemia and CKD, take into account patient preferences, symptoms, comorbidities, and the required treatment.
i
The decision on whether and when to begin ESA therapy in patients with nondialysis CKD should be individualized and take into account the rate of fall of Hb, prior response to iron therapy,
risk of transfusion, risks related to ESA therapy, and the presence of symptoms attributable to anemia. Hb values should not routinely be allowed to fall to ,100 g/L in patients with nondialysis
CKD. Therapy with ESAs should not be started if there is a temporary and obvious cause of anemia that is potentially reversible. Risk factors for stroke, a history of malignancy, or the presence of
active malignancy should be considered when weighing the risk-to-beneﬁt ratio of ESA therapy.

ERBP (8,86)

Guideline

Table 1. (Continued)
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Attempting to attain the higher Hb concentrations required
higher doses of epoetin, and these doses were associated
with more AEs. The CHOIR Study also indicated no signiﬁcant increase in overall HRQoL outcomes at higher Hb
values. The placebo–controlled Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), which evaluated patients with CKD and type 2 diabetes, found no
differences in the composite primary end point of mortality and cardiovascular comorbidities, whereas there was
increased risk of stroke and neoplasia in ESA-treated patients; however, a secondary analysis showed that patients
in the ESA group reported a signiﬁcant improvement in
fatigue compared with those in the placebo group as well
as numerically, but not signiﬁcantly, higher improvements
in other HRQoL measures in the ESA group (32).
In the United States, EPO dosages decreased by about
20% from 2005 to 2009 among patients with ND-CKD (33).
Additionally, an analysis of ESA use among the ND-CKD
population in the United States before and after the release
of results from the TREAT showed that, in the 2 years after
the release of the study results, ESA use declined 38% and
22% among patients with ND-CKD stage 3 or 4, respectively (34). Also, a 15% decrease was observed in Hb levels
.120 g/L among patients with ND-CKD (33,35). In 2011,
the FDA changed ESA prescribing to remove the target Hb
range of 10–12 g/dl and replaced it with the recommendation to consider initiating ESA treatment when Hb is
,10 g/dl and symptoms of anemia are present (36).
In contrast to the trends observed in the United States,
between 2008 and 2013 in Sweden, ESA doses slightly
increased among patients with ND-CKD (37). In Taiwan,
restrictive criteria for ESA reimbursement were introduced
by the National Health Insurance Administration in 1996,
resulting in much lower ESA dosing and use (38). These
guidelines provide strict criteria for when ESA therapy can
be initiated in patients with ND-CKD (serum creatinine
.6 mg/dl and a hematocrit ,28% to maintain a hematocrit level not exceeding 30%), limiting its use in this patient
population (38).

Iron Therapy
The treatment guidelines universally recommend iron
therapy to correct iron deﬁciency in patients with ND-CKD
(Table 1); however; the type of iron therapy and route of
administration have been topics of much controversy, with
differences observed regionally. In patients with ND-CKD
in Sweden, oral iron therapy decreased from 15.1% in 2008
to 11.0% in 2013, whereas iv iron administration increased
from 3.8% in 2008 to 5.5% in 2013 (37). Although changes
in iron therapy administration among the ND-CKD population have not been collected in the United States or
many other regions of the world, trends in recent years
in the United States among the dialysis CKD population
have shown an increase in iv iron administration (39). The
reason for these regional differences in iron use could be
because of differences in guidelines, but there are not
enough data regarding the ND-CKD population at this
time to draw such conclusions. The CKD Outcomes and
Practice Patterns Study team is a collaborative research
relationship among experts in France, Germany, Brazil,
and the United States that uses its international scope to

facilitate comparisons of nephrology practices in different
countries. The overall goal is to develop an evidence base
for the effective treatment of advanced CKD, thereby improving care and outcomes for future patients. Numerous
topics are currently being explored, including anemia;
thus, these studies may provide insight into these trends
in the future.
Changes in iron therapy trends have been observed
regionally and over the past decade, and ferritin levels in
the dialysis population have shown increasing variation
among countries, with the United States presenting with
the highest national average of ferritin and Japan showing
the lowest (40). These country-speciﬁc differences are not
as clearly identiﬁed in the ND-CKD population. In the
latest study from Sweden of patients with ND-CKD, average serum ferritin levels did not change signiﬁcantly over
the period from 2008 to 2013, despite increases in iv iron
use over that same period (37). It would be interesting to
identify whether the increase in ferritin levels within the
United States CKD population occurs earlier during disease management or if the increase in ferritin coincides
with the incidence of dialysis. Despite the recognition
that ferritin is a poor marker of iron stores, it remains to
be identiﬁed if elevated levels of ferritin contribute to
poorer outcomes, especially in patients with ND-CKD.
For example, a prospective study in patients with NDCKD showed a dose dependency between iv iron doses
and liver iron concentration; however, no dose dependency was observed in changes in serum ferritin or
TSAT concentrations (18,41–43).
Iron supplementation can be administered by iv and oral
routes (1,2,7,8). The KDIGO guidelines recommend that,
for patients with ND-CKD who require iron supplementation, the route of iron administration should be selected
on the basis of severity of iron deﬁciency, availability of
venous access, response to prior oral iron therapy, side effects with prior oral or iv iron therapy, patient adherence,
and cost (1). Health care providers have begun reconsidering oral iron therapy over iv iron therapy, particularly for
the ND-CKD population, for multiple reasons, including
safety concerns regarding the regulation of iv iron, ease of
administration, vein preservation for future vascular access, and cost. Typical AEs associated with oral iron administration are nausea, vomiting, constipation, and a
metallic taste, which are usually reported as relatively
mild in intensity (44).

iv Iron Therapies
iv Iron was evaluated for treating anemia as early as 1932
(45), but the 10% ferric ammonium citrate formulation produced severe AEs. Updated iv iron formulations were introduced for treating anemia beginning in 1964. Early iv
iron formulations, such as high molecular weight dextran,
raised concerns of severe anaphylactoid reactions (46).
Newer formulations have sought to reduce immunogenicity by reducing the size and branch characteristics of the
polysaccharide, which may reduce some of the safety issues associated with earlier formulations (47).
Moreover, treatment with iv iron has also raised more
serious safety concerns, such as for renal injury (48), cardiovascular injury (49), calciphylaxis (50), and labile iron
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toxicity (51). The administration of iv iron has been shown
to cause oxidative stress from large amounts of iron being
introduced in the blood during a single infusion (48). In an
in vitro study comparing iv iron dextran, iron sucrose, iron
gluconate, and iron oligosaccharide, all formulations produced oxidative stress, which was shown by increases in
lipid peroxidation (52). However, differences in cell death
were observed in this study where ferric sucrose caused
the highest rate of cell death, followed by ferric glucose,
ferric dextrose, and ferric oligosaccharide, indicating signiﬁcantly different toxicity proﬁles (52). These in vitro data
have been supported by animal studies (53) as well as
studies in patients on hemodialysis (54,55) and patients
with ND-CKD (56). In a study of patients with ND-CKD
treated with iv ferric carboxymaltose, levels of both oxidative stress and inﬂammatory markers increased after iron
treatment, regardless of response to the iron therapy (56).
Oxidative stress markers analyzed included oxidized low–
density lipid protein, protein carbonyl groups, erythrocyte
superoxide dismutase, and glutathione peroxidase. Glutathione peroxidase activity was lower in nonresponders
compared with responders; however, levels of all other
oxidative stress markers did not show signiﬁcant differences
between the two groups. The long-term effects of such iron–
induced oxidative stress have not been determined.
Recent clinical trial results have continued to present
conﬂicting efﬁcacy and safety conclusions regarding the
use of iv iron to treat anemia in the ND-CKD population. In
the randomized, clinical trial the Randomized Trial to
Evaluate Intravenous and Oral Iron in Chronic Kidney
Disease (REVOKE) that investigated iv iron sucrose (200 mg
once every 2 weeks for a total of 1 g) versus oral ferrous
sulfate (325 mg three times daily for 8 weeks) in patients
with ND-CKD and moderate to severe anemia, efﬁcacy
measurements were similar between the two treatment
groups. However, the trial was terminated early because of
an increased risk of serious AEs, particularly cardiovascular AEs and infections, in the iv iron treatment group (57).
In contrast, another randomized clinical trial known as the
Ferinject Assessment in Patients with Iron Deﬁciency Anemia and Non-Dialysis-Dependent Chronic Kidney Disease
Study evaluated the difference between iv ferric carboxymaltose (high [1000 mg followed by 500–1000 mg every 4
weeks depending on ferritin level] and low [200 mg followed by 200 mg every 4 weeks] doses) and oral iron therapy (100 mg ferrous sulfate twice daily) in the same
population and found that iv iron therapy was more effective in reaching and maintaining Hb levels and reduced
the need for additional anemia management (58). The investigators did not observe the same increase in serious
AEs as those reported in the REVOKE. Similarly, in an
open-label clinical trial comparing iv ferric carboxymaltose
(1000 mg up to three times over 8 weeks) with oral ferrous
sulfate (325 mg three times daily), statistically signiﬁcant
increases in Hb, ferritin, and TSAT were observed in the
iv versus oral group, with signiﬁcantly fewer treatment–
related AEs in the iv iron group (59). A recent phase 3, openlabel clinical study compared the use of iv iron isomaltoside
1000 (500–1000 mg weekly) with oral ferrous sulfate (100 mg
twice daily) in ESA-naïve patients with ND-CKD over 8
weeks and found that the iv iron group had statistically
signiﬁcant improvement of iron deﬁciency markers,
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including Hb, serum ferritin, and TSAT concentrations,
over the oral iron group (60). A similar number of AEs
was reported in each treatment group; however, a larger
percentage of patients in the oral ferrous sulfate group
(4.3% versus 0.9%) discontinued the trial because of AEs.
Thus, safety results in regards to iv iron administration are
different among studies, and the long-term consequences of
continued iv iron are yet to be determined.
Other considerations for iv versus oral iron administration include ease of administration and cost. Oral iron is
inexpensive and administered at home. Patients receiving iv iron are required to visit a health care facility for
treatment by a skilled health care professional. Although
considered rare, AEs (especially with ﬁrst treatment or
initiation of a new formulation), including acute chest and
back tightness, allergic reactions, or anaphylactic shock (61),
can occur, and, thus, the iv iron therapies should only be
administered in facilities where resuscitation and treatments for anaphylaxis are readily available (62). Although
rare, the chance of allergic reactions with iron treatment
prompted the European Medicines Agency to release new
recommendations to manage the risk of allergic reactions
with iron-containing medicines in 2013 (63). In addition,
recurrent infusions of iron can lead to problems with venous anatomy and quality, thereby compromising future
vascular access construction (1), which needs to be preserved for potential future hemodialysis treatments.

Oral Iron Therapies
The use of oral iron in medicine has a more colorful
history (64). Although oral ferrous sulfate was empirically
prescribed as early as the 1700s to treat “chlorosis” in adolescent girls, which was characterized by “pale color, palpitation of the heart,” and “confusion of the spirits,” it was
only in the 1830s that any rationale for this treatment for
anemia was provided (64). Still, it remained contested into
the late 1890s whether inorganic iron could be incorporated into Hb, and the relationship between oral iron
and anemia was ﬁnally accepted with the advent of radioactive tracer experiments in the late 1930s that showed gut
iron absorption (64).
The bioavailability of oral iron sources has been a major
concern for the treatment of anemia. Iron is absorbed in the
intestine in a highly regulated metabolic cycle. Hepcidin
has been shown to be an important regulator of iron
metabolism by inhibiting release of intestinal iron being
absorbed into the blood (65). Hepcidin inhibition increases
during states of inﬂammation, such as inﬂammation experienced by patients with CKD, and during iron overload,
resulting in decreased iron absorption (Figure 1) (65,66).
Thus, new oral iron therapies are required to provide efﬁcacy with better patient compliance. The most promising
of the new therapies along with conventional options for
oral iron supplementation are reviewed in Table 2, and a
summary of oral iron therapies is also provided in Table 2.
Iron Salts
Iron salts have historically been the most common form
of oral iron supplementation used in patients with NDCKD. Iron salts exist as the ferrous (Fe21) and ferric (Fe31)
forms. For gut absorption, iron must be in the ferrous

FeSO4
FeSO4
FeSO4

FeSO4
FeSO4
FeSO4
FeSO4
C4H2FeO4
FeC3H5O (COO)3

FeC3H5O (COO)3

Ferrous sulfate
Ferrous sulfate
Ferrous sulfate

Ferrous sulfate
Ferrous sulfate
Ferrous sulfate
Ferrous sulfate
Ferrous fumarate
Ferric citrate

Ferric citrate
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12 wk

X

X

X

X
X
X
X
X
X

X
—
—

56 d
12 mo
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29 d
56 d
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21 d
12 wk

X

X
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—
X
—
NR
X
X

—
X
—
X
X
X

X
—

X
—

X

X
—
X

—
—
X

X

X

X

TSAT

X

X

Fer

Efﬁcacy Measuresa

52 wk

8 wk

Therapy
Duration

3.1d

NR

69.3

NR
19
NR
NR
52
68.3

59.2
NR
20d

81.7

68.1

Frequency, %

b

c

Stool discoloration, URI, diarrhea,
traumatic injury, fall, constipation,
dyspnea, chest pain, dizziness, UTI,
hyperkalemia, hypertension
Diarrhea, constipation, hypertension,
peripheral edema, dyspepsia, UTI,
nasopharyngitis
Constipation
NR
Constipation, stool discoloration, nausea,
diarrhea
NR
Constipation, diarrhea, nausea, vomiting
NR
NR
Constipation, diarrhea
Diarrhea, constipation, abdominal
discomfort, abdominal distensione
Stool discoloration, diarrhea, constipation,
nausea, vomiting, URI
Constipation, abdominal cramps, muscle
cramps, bloating, diarrhea, nausea
—

Most Common Adverse Events

Adverse Events

Pisani et al. (81)

Nagaraju et al. (80)

Block et al. (74)

Charytan et al. (89)
Van Wyck et al. (90)
Aggarwal et al. (91)
Stoves et al. (92)
Spinowitz et al. (93)
Yokoyama et al. (94)

Qunibi et al. (59)
McMahon et al. (87)
Agarwal et al. (88)

Macdougall et al. (58)

Agarwal et al. (57)

Studies in
Nondialysis CKD

Hb, hemoglobin; Fer, ferritin; TSAT, transferrin saturation, X, evidence of therapeutic efﬁcacy for the given measure; URI, upper respiratory tract infection; UTI, urinary tract infection; —, lack of
efﬁcacy evidence; NR, not reported.
a
Assessed at the conclusion of treatment.
b
Unless otherwise noted, percentage of subjects experiencing at least one adverse event.
c
Unless otherwise noted, most common treatment–emergent adverse events occurring in $5% of participants.
d
Percentage of subjects experiencing at least one treatment–related adverse event.
e
Most common treatment–emergent and –related adverse events occurring in $5% of participants.

Liposomal iron

Fe4(P2O7)3

FeSO4

Ferrous sulfate

Heme iron

FeSO4

Chemical Formula

Ferrous sulfate

Therapy

Table 2. Oral iron supplementation therapies in patients with nondialysis-dependent CKD
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form; thus, dietary ferric iron is reduced to the ferrous
form to be absorbed (67). Prescribed oral iron salt preparations are in the ferrous form, including ferrous sulfate,
ferrous fumarate, ferrous gluconate, and polysaccharide
iron complex (68). Among these, ferrous sulfate is by far
the most frequently prescribed for treating anemia in patients with ND-CKD (44). These oral iron salts have been
shown to increase Hb, ferritin, and TSAT in this population (69,70). Administration of these iron salts can
produce a rapid release of iron ions in the gastrointestinal
tract, leading to oxidative stress and resulting AEs, particularly those affecting the gastrointestinal tract (67,71).
Mild to moderate AEs of constipation, nausea, vomiting,
and diarrhea are often reported in trials of oral iron salts,
such as ferrous sulfate, but serious AEs related to treatment are rare. Recent evidence has also suggested that
unabsorbed oral iron can lead to changes in the intestinal
microbiome by stimulating the growth of bacterial pathogens, which threaten the natural microbiota of the gut and
lead to additional AEs (72). Because of frequent gastrointestinal side effects, patients with ND-CKD often have reduced adherence to oral iron therapy (44).
Iron–Based Phosphate Binders
Ferric citrate is an oral compound comprising trivalent
iron with citrate. Originally developed and approved for
use as a phosphate binder, it is water soluble and dissociates
into ferric iron and citrate in the intestinal lumen (73). In a
phase 2 study in patients with ND-CKD to evaluate the
change in serum phosphate and TSAT, ferric citrate increased measures of iron repletion, including Hb, ferritin,
and TSAT (74). As with other iron preparations, the most
frequently observed AEs with ferric citrate were gastrointestinal (74). A phase 3 trial (NCT02268994) is currently
underway in the United States to evaluate the effect of
ferric citrate on changes in Hb compared with placebo in
patients with ND-CKD. Sucroferric oxhydroxide is another
iron–based phosphate binder recently approved for treatment of patients with CKD; however, the clinical trials
showed no clinical or statistical increase in iron parameters
when used as a phosphate binder in patients with CKD on
dialysis (75).
Recent studies of the molecular mechanism of phosphate
homeostasis have suggested a link between hyperphosphatemia and iron deﬁciency through the key regulatory
hormone FGF23 (11). In addition, a historical population–
based study found that higher phosphorus levels in patients
with early CKD resulted in a greater chance of having anemia
(76). Interestingly, ferric citrate, being administered with meals
as a phosphate binder, has been shown to reduce FGF23 and
increase iron parameters in ND-CKD (74).
Heme Iron Polypeptide
Heme iron polypeptide is an oral iron therapy that uses
the heme porphyrin ring to supply iron to sites of absorption in the intestinal lumen (77). Because heme iron is absorbed via a different receptor than in nonheme (ionic)
iron, the bioavailability of heme iron polypeptide in
healthy individuals is signiﬁcantly greater than that for
nonheme iron (78). However, this increase has not uniformly translated into markedly improved outcomes in
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clinical studies (79). Nevertheless, heme iron polypeptide
increases levels of Hb, ferritin, and TSAT in patients with
ND-CKD (80).
As with other forms of oral iron supplementation, AEs
associated with heme iron polypeptide therapy are primarily related to the gastrointestinal system in patients
with ND-CKD. These AEs occurred at a frequency similar
to that observed with iv iron therapy, including constipation, abdominal cramps, muscle cramps, bloating, diarrhea,
and nausea (80).
Liposomal Iron
Liposomal iron is an oral iron preparation in which iron,
as ferric pyrophosphate, is carried within a phospholipid
membrane. Liposomal iron does not directly contact the
intestinal mucosa before its release by liver enzymes.
Consequently, this method of iron supplementation is
associated with high gastrointestinal absorption, high bioavailability, and a low incidence of side effects (77).
Liposomal iron is an investigational drug currently under study. AEs associated with liposomal iron therapy in
patients with ND-CKD occur at a lower frequency than
typically observed for other oral or iv iron supplementation
strategies (81). These AEs are generally mild and primarily
related to the gastrointestinal system, with the most common being constipation, diarrhea, nausea, and headache.
This therapy increases iron stores and Hb levels in patients
with ND-CKD, but early data suggest that it does so less
effectively than iv iron therapy (81).
Other Approaches to Treat Iron Deficiency Anemia in
Patients with CKD
Although ESAs and iron therapy continue to be the main
therapies used in the treatment of anemia in patients with
CKD, other approaches to anemia treatment are currently
being investigated in clinical studies. These include hypoxia–
inducible factor stabilizers and hepcidin modulators (82).
In addition to ESA and iron therapies, these could offer
alternative or complementary therapies for the treatment
of anemia in patients with CKD.

Conclusions
Despite disparities regarding target iron levels and the
absence of reliable markers of iron deﬁciency, the importance of correcting iron deﬁciency in patients with CKD is
indisputable. Oral iron therapies offer safe and effective
options to treat iron deﬁciency anemia in patients with
CKD in a physiologic way. In contrast to iv iron therapies,
oral iron treatments require few resources for administration
and are not associated with potential serious AEs. However,
traditional oral iron treatments are not optimal because of
increased gastrointestinal AEs, lack of patient adherence,
and very often, lack of efﬁcacy in patients with stage 5 CKD.
Overall, treatments currently under development for iron
deﬁciency anemia may represent an improvement in therapeutic options to treat iron deﬁciency anemia.
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